Ratings ONCS BRAS

Equities

Market Closed - Sao Paulo Other stock markets 04:06:00 2024-05-10 pm EDT			5-day change	1st Jan Change
6.98 ^BRL	+15.37%		-3.99%	-46.31%

Mar. 27	Oncoclínicas do Brasil Serviços Médicos S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 27	Oncoclínicas do Brasil Serviços Médicos S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
The company appears to be poorly valued given its net asset value.
The company has a low valuation given the cash flows generated by its activity.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the past twelve months, EPS forecast has been revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Historically, the company has been releasing figures that are above expectations.

The group shows a rather high level of debt in proportion to its EBITDA.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality